Responses
Regular and young investigator award abstracts
Clinical trials in progress
376 A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors
Compose a Response to This Article
Other responses
No responses have been published for this article.
